Replimune Appoints Christy Oliger to its Board of Directors Woburn, MA

Appoints Christy Oliger to its Board of Directors

Woburn, MA, December 2, 2021

- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic

immuno-gene therapy platform, today announced the appointment of Christy Oliger to the Company's Board of Directors effective December

"We are delighted to welcome Christy to Replimune's Board

of Directors," said Philip Astley-Sparke, Chief Executive Officer of Replimune. "Christy brings nearly 30 years of commercial

and business experience in the pharmaceutical and biotechnology industry foremostly in oncology. We look forward to working with Christy

and believe her guidance and input will strengthen our board as we advance our leading pipeline of oncolytic immunotherapies to market."

Previously Ms. Oliger was Senior Vice President of the Oncology Business

Unit at Genentech responsible for all commercial activities in the US. Ms. Oliger spent two decades with Genentech, holding a number of

leadership roles including Senior Vice President, IMPACT Business Unit; Vice President, Pharma Portfolio Management; Vice President, Portfolio

Planning and Vice President, Hematology Marketing and Sales. Prior to Genentech, Ms. Oliger held management positions at Schering-Plough.

Ms. Oliger currently serves as a member of the board of Karyopharm Therapeutics Inc., Reata Pharmaceuticals, Inc. and Sierra Oncology,

Ms. Oliger holds a bachelor's degree in Economics from the University

of California at Santa Barbara.

Replimune Group, Inc., headquartered in Woburn, MA, was founded in

2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary

therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response

to the tumor antigens released. Replimune's Immulytic platform is designed to maximize systemic immune activation, in particular

to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating

proteins to the tumor and draining lymph nodes. The approach is expected to be highly synergistic with immune checkpoint blockade and

other approaches to cancer treatment across a broad range of cancers. Replimune intends to progress these therapies rapidly through clinical

development in combination with other immuno-oncology products with complementary mechanisms of action as well as in standalone indications. For

more information, please visit www.replimune.com.

Forward Looking Statements

This press release contains forward looking statements within the meaning

of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including

statements regarding the design and advancement of our clinical trials, the timing and sufficiency of our clinical trial outcomes to support

potential approval of any of our product candidates, our goals to develop and commercialize our product candidates, patient enrollments

in our existing and planned clinical trials and the timing thereof, the potential impact of the global coronavirus pandemic and the global

economy on our operations and milestones, and other statements identified by words such as "could," "expects,"

"intends," "may," "plans," "potential," "should," "will," "would,"

or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance,

and are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to

differ materially from those contemplated in such forward-looking statements. These factors include risks related to our limited operating

history, our ability to generate positive clinical trial results for our product candidates, the costs and timing of operating our in-house

manufacturing facility, the timing and scope of regulatory approvals, changes in laws and regulations to which we are subject, competitive

pressures, our ability to identify additional product candidates, political and global macro factors including the impact of the coronavirus

as a global pandemic and related public health issues, and other risks as may be detailed from time to time in our Annual Reports on Form

10-K and Quarterly Reports on Form 10-Q and other reports we file with the Securities and Exchange Commission. Our actual results could

differ materially from the results described in or implied by such forward-looking statements. Forward-looking statements speak only as

of the date hereof, and, except as required by law, we undertake no obligation to update or revise these forward-looking statements.

Verge Scientific Communications